Gilead Sciences Inc

Latest articles

2d
FOX Business
3 Biotech Stocks With Major Catalysts IncomingAxovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc.(NASDAQ: PTCT) ha
FOX Business / Posted 2 days ago
Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc.(NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences, Inc.(NASDAQ: GILD) is already one of the most... Read more
2d
FOX Business
3 Biotech Stocks With Major Catalysts IncomingAxovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc.(NASDAQ: PTCT) ha
FOX Business / Posted 2 days ago
Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc.(NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences, Inc.(NASDAQ: GILD) is already one of the most... Read more
5d
Swissinfo
All Swiss hepatitis C sufferers can access costly drugs like Harvoni2006. Price point The recent changes result from negotiations between the hea
Swissinfo / Posted 5 days ago
2006. Price point The recent changes result from negotiations between the health office and the biopharmaceutical company Gilead Sciences Inc, which accepted sizeable price reductions of Harvoni and Epclusa, the health office declared. The Swiss... Read more
9d
Business Wire
Gilead Prices $3 Billion of Senior Unsecured NotesFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today
Business Wire / Posted 9 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of four... Read more
4 related articles
22d
FOX Business
You Reached Retirement: 3 Stocks to Consider Todaywould be wise to consider. Read on to learn why they chose Five Below(NASDAQ: F
FOX Business / Posted 22 days ago
would be wise to consider. Read on to learn why they chose Five Below(NASDAQ: FIVE), Cisco Systems(NASDAQ: CSCO), and Gilead Sciences (NASDAQ: GILD). A trendy long-term investment Steve Symington (Five Below): The irony of recommending Five... Read more
22d
FOX Business
You Reached Retirement: 3 Stocks to Consider Todaywould be wise to consider. Read on to learn why they chose Five Below(NASDAQ: F
FOX Business / Posted 22 days ago
would be wise to consider. Read on to learn why they chose Five Below(NASDAQ: FIVE), Cisco Systems(NASDAQ: CSCO), and Gilead Sciences (NASDAQ: GILD). A trendy long-term investment Steve Symington (Five Below): The irony of recommending Five... Read more
23d
Swissinfo
Today's Miracle Is Tomorrow's Also-Ran in Hottest Cancer Fieldfight against cancer. Novartis AG got approval for the first treatment in a rev
Swissinfo / Posted 23 days ago
fight against cancer. Novartis AG got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on their laurels.... Read more
300 related articles
23d
Business Wire
Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today
Business Wire / Posted 23 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young CBE, Gilead’s Chief Operating Officer, Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief Scientific Officer, and... Read more
23d
New York Post
Cancer drug a major breakthrough — but it has a hefty price tagin a statement. The FDA said it has granted 76 applications for trials involvi
New York Post / Posted 23 days ago
in a statement. The FDA said it has granted 76 applications for trials involving experimental CAR-T therapies. Shares of Gilead Sciences Inc, which this week announced an $11.9 billion deal to buy Kite Pharma, were up 6.2 percent to $80.47 on... Read more
300 related articles
24d
Market Watch
Novartis’ CAR-T therapy was the first approved in U.S. — here’s how to invest in the spaceinnings of a potential decade-long growth cycle,” said Janney analyst Paul Knig
Market Watch / Posted 24 days ago
innings of a potential decade-long growth cycle,” said Janney analyst Paul Knight. Kite Pharma — which will be acquired by Gilead Sciences Inc. for $11 billion, in a deal made public earlier this week — should get its own CAR-T therapy approved by... Read more
300 related articles
24d
Newsmax
Novartis Gene Therapy Approval Signals New Cancer Treatment Eraattack a deadly cancer,” U.S. Food and Drug Administration Commissioner Scott G
Newsmax / Posted 24 days ago
attack a deadly cancer,” U.S. Food and Drug Administration Commissioner Scott Gottlieb said in a statement. U.S. biotech Gilead Sciences Inc jumped into the field this week with its announcement of an $11.9 billion deal to buy Kite Pharma. Gilead... Read more
300 related articles
24d
FOX Business
Why Analog Devices, Gilead Sciences, and Universal Display Jumped Todaysaw the best performance, climbing 1.1%. Good news from a few select companies
FOX Business / Posted 24 days ago
saw the best performance, climbing 1.1%. Good news from a few select companies produced solid gains, and Analog Devices, Inc. (NASDAQ: ADI), Gilead Sciences, Inc.(NASDAQ: GILD), and Universal Display Corporation(NASDAQ: OLED) were among the best... Read more
24d
FOX Business
Why Analog Devices, Gilead Sciences, and Universal Display Jumped Todaysaw the best performance, climbing 1.1%. Good news from a few select companies
FOX Business / Posted 24 days ago
saw the best performance, climbing 1.1%. Good news from a few select companies produced solid gains, and Analog Devices, Inc. (NASDAQ: ADI), Gilead Sciences, Inc.(NASDAQ: GILD), and Universal Display Corporation(NASDAQ: OLED) were among the best... Read more
25d
Brainerd Dispatch
FDA approves breakthrough treatment for dire cancersin remission within three months, according to Novartis. The approval of Novar
Brainerd Dispatch / Posted 25 days ago
in remission within three months, according to Novartis. The approval of Novartis' CAR-T therapy comes just two days after Gilead Sciences Inc. announced an agreement to spend $11.9 billion and buy Kite Pharma Inc., which is developing its own... Read more
300 related articles
25d
Business Wire
Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences, Inc. is Fair to Shareholdersfollowing statement is being issued by Levi & Korsinsky, LLP: To: All Persons
Business Wire / Posted 25 days ago
following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Kite Pharma, Inc. ("Kite Pharma" or the "Company") (NASDAQ: KITE) stock prior to August 28, 2017. You are hereby notified that Levi &... Read more
5 related articles
25d
Orlando Sentinel
Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billionSanta Monica biotech company Kite Pharma Inc. is being acquired by industry gia
Orlando Sentinel / Posted 25 days ago
Santa Monica biotech company Kite Pharma Inc. is being acquired by industry giant Gilead Sciences Inc. in an $11.9-billion deal that demonstrates the promise of using a person’s own immune system to fight cancer. Foster City-based Gilead said Monday... Read more
42 related articles
25d
Los Angeles Times
FDA clears first ‘living drug' to treat tough childhood leukemiaare being tracked to see how they fare in the long term. Kite Pharma Inc., a S
Los Angeles Times / Posted 25 days ago
are being tracked to see how they fare in the long term. Kite Pharma Inc., a Santa Monica biotech company, is working separately on CAR-T cell treatment. On Monday, Gilead Sciences Inc. announced that it was buying Kite in an $11.9-billi... Read more
300 related articles
25d
Market Watch
Novartis AG's CAR-T cell therapy for leukemia approved by FDA in 'historic action'; price to be based on outcomesis also working in the CAR-T space, has also been racing to gain FDA approval;
Market Watch / Posted 25 days ago
is also working in the CAR-T space, has also been racing to gain FDA approval; the biotech's $11 billion acquisition by Gilead Sciences Inc. GILD, +5.06% was reported earlier this week. Gilead shares surged 5.5% in extremely heavy midday trade.... Read more
300 related articles
26d
FOX Business
Can Gilead Sciences Squeeze $12 Billion From Kite Pharma?Gilead Sciences, Inc. (NASDAQ: GILD) just took a bold leap into the unknown wit
FOX Business / Posted 26 days ago
Gilead Sciences, Inc. (NASDAQ: GILD) just took a bold leap into the unknown with an agreement to acquire Kite Pharma Inc.(NASDAQ: KITE) for $180 per share or about $11.9 billion. Gilead's last 11-figure bet turned out to be one of the best... Read more
42 related articles
26d
FOX Business
Can Gilead Sciences Squeeze $12 Billion From Kite Pharma?Gilead Sciences, Inc. (NASDAQ: GILD) just took a bold leap into the unknown wit
FOX Business / Posted 26 days ago
Gilead Sciences, Inc. (NASDAQ: GILD) just took a bold leap into the unknown with an agreement to acquire Kite Pharma Inc.(NASDAQ: KITE) for $180 per share or about $11.9 billion. Gilead's last 11-figure bet turned out to be one of the best... Read more
42 related articles
26d
Income Investors
Gilead Sciences, Inc.: Is GILD Worth an Investment? iStock.com/CI_ROMEGILD Stock Pays out a Growing Dividend When looking at a p
Income Investors / Posted 26 days ago
iStock.com/CI_ROMEGILD Stock Pays out a Growing Dividend When looking at a potential investment opportunity, there are a few important things to consider, such as how shareholders are treated,... Read more
26d
Zero Hedge
August 29the northern island of Hokkaido, South Korea and Japan said, in a sharp escalat
Zero Hedge / Posted 26 days ago
the northern island of Hokkaido, South Korea and Japan said, in a sharp escalation of tensions on the Korean peninsula. * Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging... Read more
26d
Profit Confidential
10 Weeks Later, Kite Pharma Stock Is Up 94.40%Stock Is Up 94.40% Patrick Brik CFA, BAS Profit Confidential 2017-08-29T07:4
Profit Confidential / Posted 26 days ago
Stock Is Up 94.40% Patrick Brik CFA, BAS Profit Confidential 2017-08-29T07:42:59Z 2017-08-29 07:42:59 kite pharma incNASDAQ:KITEKITE stockkite pharma stockKITE stock pricekite pharma stock chartKITE price chartpharma stock10 weeks ago, I... Read more
26d
The Economic Times
AirAsia Q2 profit falls 73 per cent on one-off tax chargeTen Network Gilead to buy Kite for $11.9 billion in cancer drug megadeal Audi
The Economic Times / Posted 26 days ago
Ten Network Gilead to buy Kite for $11.9 billion in cancer drug megadeal Audi announces reshuffle of management board Gilead Sciences Inc to buy Kite Pharma in $11 billion deal Braving security fears, Chinese seek 'Silk Road' riches in... Read more
2 related articles
26d
The Economic Times
Renault-Nissan, China's Dongfeng announce e-car ventureTen Network Gilead to buy Kite for $11.9 billion in cancer drug megadeal Audi
The Economic Times / Posted 26 days ago
Ten Network Gilead to buy Kite for $11.9 billion in cancer drug megadeal Audi announces reshuffle of management board Gilead Sciences Inc to buy Kite Pharma in $11 billion deal Braving security fears, Chinese seek 'Silk Road' riches in... Read more
2 related articles
26d
FOX Business
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Todayhigh-profile announcements regarding acquisitions that played into broad gains
FOX Business / Posted 26 days ago
high-profile announcements regarding acquisitions that played into broad gains in a couple of sectors. Thor Industries, Inc.(NYSE: THO), IXYS Corporation(NASDAQ: IXYS), and Kite Pharma, Inc. (NASDAQ: KITE) were among the best performers of the... Read more
26d
FOX Business
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Todayhigh-profile announcements regarding acquisitions that played into broad gains
FOX Business / Posted 26 days ago
high-profile announcements regarding acquisitions that played into broad gains in a couple of sectors. Thor Industries, Inc.(NYSE: THO), IXYS Corporation(NASDAQ: IXYS), and Kite Pharma, Inc. (NASDAQ: KITE) were among the best performers of the... Read more
26d
Newsmax
Gilead to Buy Kite Pharma in Cancer Drug MegadealGilead Sciences Inc. will buy Kite Pharma Inc. for about $11.9 billion, making
Newsmax / Posted 26 days ago
Gilead Sciences Inc. will buy Kite Pharma Inc. for about $11.9 billion, making one of its biggest-ever deals for a breakthrough new cancer treatment and helping it diversify away from its eroding franchise of medicines for hepatitis C... Read more
42 related articles
27d
The Economic Times
Gilead to buy Kite for $11.9 billion in cancer drug megadealBERLIN: Gilead Sciences Inc agreed to buy Kite Pharma Inc for about $11.9 billi
The Economic Times / Posted 27 days ago
BERLIN: Gilead Sciences Inc agreed to buy Kite Pharma Inc for about $11.9 billion, making one of its biggest deals ever to expand beyond its eroding hepatitis C drug franchise. With Kite, Gilead will gain cancer therapies and experimental drugs in... Read more
42 related articles
27d
Darien News-Review
Gilead to pay $11.9B for cancer treatment developer Kitegene therapy available in the United States, with approval possible as early as
Darien News-Review / Posted 27 days ago
gene therapy available in the United States, with approval possible as early as September. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
The Fairfield Citizen
Gilead to pay $11.9B for cancer treatment developer Kitegene therapy available in the United States, with approval possible as early as
The Fairfield Citizen / Posted 27 days ago
gene therapy available in the United States, with approval possible as early as September. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
Stamford Advocate
Gilead to pay $11.9B for cancer treatment developer Kitegene therapy available in the United States, with approval possible as early as
Stamford Advocate / Posted 27 days ago
gene therapy available in the United States, with approval possible as early as September. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
The Greater New Milford Spectrum
Gilead to pay $11.9B for cancer treatment developer Kitegene therapy available in the United States, with approval possible as early as
The Greater New Milford Spectrum / Posted 27 days ago
gene therapy available in the United States, with approval possible as early as September. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
The New Canaan News
Gilead to pay $11.9B for cancer treatment developer Kitegene therapy available in the United States, with approval possible as early as
The New Canaan News / Posted 27 days ago
gene therapy available in the United States, with approval possible as early as September. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
Connecticut Post
Gilead to pay $11.9B for cancer treatment developer Kitegene therapy available in the United States, with approval possible as early as
Connecticut Post / Posted 27 days ago
gene therapy available in the United States, with approval possible as early as September. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
Newsmax
Gilead to Buy Cancer Biotech Kite for $11.9 BillionGilead Sciences Inc. will buy Kite Pharma Inc. for about $11.9 billion, making
Newsmax / Posted 27 days ago
Gilead Sciences Inc. will buy Kite Pharma Inc. for about $11.9 billion, making one of its biggest-ever deals for a breakthrough new cancer treatment and helping it diversify away from its eroding franchise of medicines for hepatitis C... Read more
42 related articles
27d
Bangkok Post - Thailand's English news
Gilead to pay $11.9bn for cancer treatment developer Kiteblood cancer closer to becoming the first gene therapy available in the United
Bangkok Post - Thailand's English news / Posted 27 days ago
blood cancer closer to becoming the first gene therapy available in the United States. Foster City, California-based Gilead Sciences Inc said that it will pay $180 for each share of Kite Pharma Inc, marking a 29% premium to the company's... Read more
42 related articles
27d
The Jewish Press
Gilead Sciences to Acquire Israeli Cancer Curing Kite Pharma for $11.9 Billion | 6 Elul 5777 – August 28, 2017Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) annou
The Jewish Press / Posted 27 days ago
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced on Monday that they have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values... Read more
42 related articles
27d
The Economic Times
Gilead Sciences Inc to buy Kite Pharma in $11 billion deal Braving security fears, Chinese seek 'Silk Road' riches in Pakistan Blacks
The Economic Times / Posted 27 days ago
Braving security fears, Chinese seek 'Silk Road' riches in Pakistan Blackstone hires Katsuyuki Kuki as chairman, representative... Read more
2 related articles
27d
Los Angeles Times
Gilead to pay $11.9 billion for cancer treatment developer Kitescience and technology have opened a clear path toward a potential cure for pat
Los Angeles Times / Posted 27 days ago
science and technology have opened a clear path toward a potential cure for patients," he said. Foster City, Calif.-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29% premium to the company's... Read more
42 related articles
27d
Business Standard India
Gilead to buy Kite Pharma for promising cancer therapies in $12 bn dealGilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Mo
Business Standard India / Posted 27 days ago
Gilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions. Gilead will pay $180 per share in an all-cash... Read more
42 related articles
27d
MyMotherLode.com
Gilead Sciences buying Kite Pharma for $11 9 billionciloleucel, is under priority review by the Food and Drug Administration as a t
MyMotherLode.com / Posted 27 days ago
ciloleucel, is under priority review by the Food and Drug Administration as a treatment for several types of lymphoma. Gilead Sciences Inc. will pay Kite Pharma Inc. $180 per share, marking a 29 percent premium to the company's closing price on... Read more
42 related articles
27d
San Antonio Express-News
Gilead to pay $11.9B for cancer treatment developer Kiteand technology have opened a clear path toward a potential cure for patients,"
San Antonio Express-News / Posted 27 days ago
and technology have opened a clear path toward a potential cure for patients," he said. Foster City, California-based Gilead Sciences Inc. said that it will pay $180 for each share of Kite Pharma Inc., marking a 29 percent premium to the... Read more
42 related articles
27d
FOX Business
Gilead Sciences buying Kite Pharma for $11.9 billionciloleucel, is under priority review by the Food and Drug Administration as a t
FOX Business / Posted 27 days ago
ciloleucel, is under priority review by the Food and Drug Administration as a treatment for several types of lymphoma. Gilead Sciences Inc. will pay Kite Pharma Inc. $180 per share, marking a 29 percent premium to the company's closing price on... Read more
42 related articles
27d
FOX Business
Gilead Sciences buying Kite Pharma for $11.9 billionciloleucel, is under priority review by the Food and Drug Administration as a t
FOX Business / Posted 27 days ago
ciloleucel, is under priority review by the Food and Drug Administration as a treatment for several types of lymphoma. Gilead Sciences Inc. will pay Kite Pharma Inc. $180 per share, marking a 29 percent premium to the company's closing price on... Read more
42 related articles
27d
KTVN Reno
Gilead Sciences buying Kite Pharma for $11.9 billionciloleucel, is under priority review by the Food and Drug Administration as a t
KTVN Reno / Posted 27 days ago
ciloleucel, is under priority review by the Food and Drug Administration as a treatment for several types of lymphoma. Gilead Sciences Inc. will pay Kite Pharma Inc. $180 per share, marking a 29 percent premium to the company's closing price on... Read more
42 related articles
27d
Reuters
Gilead to buy Kite Pharma in $11 billion deal(Reuters) - Gilead Sciences Inc has agreed to buy Kite Pharma Inc for about $11
Reuters / Posted 27 days ago
(Reuters) - Gilead Sciences Inc has agreed to buy Kite Pharma Inc for about $11 billion in an all-cash deal, the Wall Street Journal reported on Monday, citing people familiar with the matter. Gilead will pay $180 per share, the report said,... Read more
27d
Business Wire
Gilead Sciences to Acquire Kite Pharma for $11.9 BillionFOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, I
Business Wire / Posted 27 days ago
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire... Read more
27d
Market Watch
Gilead to buy Kite Pharma for about $11 blnGilead Sciences Inc. has agreed to pay about $11 billion for Kite Pharma Inc. a
Market Watch / Posted 27 days ago
Gilead Sciences Inc. has agreed to pay about $11 billion for Kite Pharma Inc. and its promising new technology for harnessing the body's immune system to fight cancer, according to people familiar with the matter. Gilead will pay $180 a share, the... Read more
42 related articles

In this news